Form 4: SPRB CEO Vests RSUs, Acquires 3,245 Net Shares

SPRUCE BIOSCIENCES CEO Javier B. Szwarcberg acquired 3,245 net shares of common stock following the vesting of performance-based Restricted Stock Units.

Summary

• Javier B. Szwarcberg, Chief Executive Officer and Director of SPRUCE BIOSCIENCES, INC. (SPRB), reported changes in his beneficial ownership.
• On October 20, 2025, 4,784 performance-based Restricted Stock Units (RSUs) vested after the Issuer's Board of Directors certified that specified performance goals were met.
• Each RSU represents a contingent right to receive one share of SPRB common stock.
• Upon vesting, 4,784 shares of common stock were acquired at an exercise price of $0.
• Concurrently, 1,539 shares were disposed of (withheld) to cover tax obligations at a price of $148.16 per share.
• The net result of these transactions is an acquisition of 3,245 shares (4,784 acquired 1,539 withheld).
• Following these transactions, Mr. Szwarcberg directly beneficially owns 9,474 shares of common stock.
• The original grant date for these performance-based RSUs was March 14, 2024.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a Form 4 for RSU vesting is a routine compensation event, the fact that performance goals were met and the CEO increased his direct ownership by 3,245 shares is a minor positive signal, indicating alignment of interests and achievement of internal targets.

Positives

• The vesting of performance-based RSUs indicates that the company's Board of Directors certified the achievement of specified performance goals, reflecting positively on company operations.
• The CEO's net acquisition of 3,245 shares increases his direct beneficial ownership, aligning management's interests with shareholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased alignment of interests between the CEO and shareholders due to higher direct stock ownership.
• Employees: The vesting of performance-based RSUs can serve as a positive signal regarding the company's ability to meet internal performance targets, potentially boosting morale.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of performance-based Restricted Stock Units and subsequent tax withholding. While the achievement of performance goals is a minor positive, this type of transaction does not fundamentally alter the company's financial outlook or strategic direction. It is a standard compensation event and does not provide new information warranting a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

SPRB, Spruce Biosciences, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, CEO, Equity Compensation, Stock Ownership